2020 Volume 43 Issue 1 Pages 1-10
The Hippo intracellular signaling pathway plays a pivotal role in cell fate determination. Although previous studies have identified many components of the Hippo pathway, the whole picture of the Hippo network is just beginning to be delineated. Recent discoveries in the past decade have shed light on a newly discovered signaling network where the Hippo pathway interplays with several types of non-coding RNAs, including microRNAs, long non-coding RNAs and circular RNAs, to mediate diverse biological processes. Those non-coding RNAs communicate with each other to maintain cellular homeostasis. In this review article, we summarize the current and emerging understanding of the roles of non-coding RNAs in the regulation of and by the Hippo pathway.
The Hippo pathway is an evolutionarily conserved signaling cascade that controls organ development,1–4) stem cell biology,5–7) regeneration,8–10) and cancer.11–13) The Hippo pathway was first identified as a key signal that contributes to the control of organ size in Drosophila melanogaster. Later observation that this pathway is conserved in mammals has attracted great interest in recent years, as experimental evidence has shown that the Hippo pathway is a main regulator of cell-fate determination, including cell proliferation, cell survival, and differentiation. Previous studies have revealed that the physiological properties of tissue architecture affect the activity of the Hippo pathway (Fig. 1). For instance, the Hippo pathway is regulated by cell–cell contact14,15) and cell polarity,16–18) as well as by mechanical cues19–23) such as extracellular matrix stiffness and traction forces exerted by neighboring cells. In addition to those physical cues, a general role of extracellular signaling pathways has become apparent, such as G-protein-coupled receptors24–27) and the Wnt signaling pathway,28–31) in the regulation of the Hippo pathway. Moreover, cellular stress signals,32–35) as well as metabolism and nutrient signals,36–41) also contribute to the regulation of the Hippo pathway. Disruption of the Hippo pathway causes tissue overgrowth and confers principal features of cancer,42–44) including increased cell proliferation and survival,45) abnormal cell division,46,47) and enhanced cell migration.48,49) In contrast, aberrant activation of the Hippo pathway impairs tissue development, stem cell maintenance, and differentiation.50) In addition to those cell-autonomous functions, recent studies revealed that the Hippo pathway also mediates non-cell autonomous functions, such as cell competition51–55) and immune responses,56–60) which play a pivotal role in the homeostatic control of multicellular organisms.61,62) Thus, collectively, the Hippo intracellular signaling pathway acts as a nexus and integrator for multiple signals from the cellular microenvironment, regulating multiple aspects of cell biology, and thereby contributing to cell-fate determination63) (Fig. 1).
The Hippo intracellular signaling pathway responds to multiple physiological cues from the cellular microenvironment, including cell–cell contact, cell polarity, mechanotransduction, extracellular signaling, and cellular stress, as well as metabolism and nutrient signals. Those signals are integrated by the Hippo pathway, and impact numerous biological processes, such as cell competition, cell migration, cell division and proliferation, cell survival, differentiation, stem cell maintenance, and immune responses. Therefore, the Hippo pathway acts as a nexus and integrator for multiple signals in the mediation of cell-fate determination.
It is therefore not surprising that a number of novel molecules and drugs are currently under development to modulate the Hippo pathway for cancer treatment and regenerative medicine.8,64) However, despite recent efforts to clarify physiological regulations of and by the Hippo pathway, the molecular mechanisms connecting those physiological cues with the Hippo pathway have not been elucidated. Previous studies established the pivotal role of protein phosphorylation in the regulation of the Hippo pathway. As the Hippo pathway responds to multiple stimuli and exerts diverse functions, it is unlikely that all of those processes are explained by biological processes mediated by proteins, such as protein–protein interaction and protein modification. Indeed, recent studies highlight important functions of metabolites in the regulation of and by the Hippo pathway.65) In this review, we aim to provide a general picture of the emerging roles of non-coding RNAs (ncRNAs) in the Hippo pathway based on current findings. Various types of ncRNA have been revealed to participate in many crucial biological processes.66,67) This emerging link between the Hippo pathway and ncRNA biology will provide a new point of view for our understanding of the biological processes mediated by the Hippo pathway, and will also likely have important clinical implications.
Since its initial discovery in fruit flies, our understanding of the Hippo signaling network has been expanding. The Hippo pathway is now known to be composed of more than 30 components.68) The heart of the Hippo pathway includes the kinase module and the transcriptional module (Fig. 2). The kinase module comprises eleven kinases, namely, mammalian STE20-like protein kinase 1 (MST1, also known as STK4) and MST2 (also known as STK3), mitogen-activated protein kinase kinase kinase kinase 1/2/3/4/5/6/7 (MAP4K1–7), large tumor suppressor kinase 1 (LATS1) and LATS2, and in addition, their activating six adaptor proteins: salvador family WW domain-containing protein 1 (SAV1), Ras-related proteins RAP2 (including three GTPases, RAP2A/B/C), and MOB kinase activator 1A (MOB1A) and MOB1B. The transcriptional module includes the two paralogues of transcriptional co-activators, yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ, also known as WWTR1), in combination with four transcription factor TEA domain family members 1/2/3/4 (TEAD1–4). When the kinase module is activated (the Hippo pathway is “ON”), MST1/2 or MAP4K1–7 phosphorylate and activate downstream LATS1/2 kinases, which in turn phosphorylate YAP/TAZ.69) Phosphorylated YAP/TAZ are retained in cytoplasm through the interaction with 14-3-3 protein,70) or degraded through the ubiquitin proteasome system.71) In contrast, when the kinase module is inactivated (the Hippo pathway is “OFF”), hypo-phosphorylated YAP/TAZ translocate to the nucleus of a cell and bind to TEAD1–4 to promote target gene transcription.72) YAP and TAZ, in complex with TEAD1–4, generally drive multiple aspects of cell-fate determination, including cell proliferation, cell survival, and differentiation, which is critical for tissue homeostasis. Thus, in short, the activation of LATS1/2 kinases and the inactivation of YAP/TAZ transcriptional co-activators represent the major molecular functions of the Hippo pathway.
The left and right panels represent the “ON” and “OFF” status of the Hippo pathway, respectively. The Hippo pathway is composed of both a kinase module and a transcriptional module. The kinase module comprises eleven kinases: mammalian STE20-like protein kinase 1 (MST1) and MST2, mitogen-activated protein kinase kinase kinase kinase 1/2/3/4/5/6/7 (MAP4K1–7), large tumor suppressor kinase 1 (LATS1) and LATS2. In addition, the kinase module requires six adaptor proteins: salvador family WW domain-containing protein 1 (SAV1), Ras-related proteins RAP2 (including three GTPases RAP2A/B/C), and MOB kinase activator 1A (MOB1A) and MOB1B. The transcriptional module includes the transcriptional co-activators, yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), associated with the transcription factors TEA domain family members 1/2/3/4 (TEAD1–4). In the left panel, when the Hippo pathway is “ON,” the kinase module inhibits the transcriptional module by mediating inhibitory phosphorylation on YAP/TAZ. Phosphorylated YAP/TAZ are retained in cytoplasm by interacting with 14-3-3 proteins, or are degraded through the ubiquitin–proteasome pathway. In contrast, when the Hippo pathway is “OFF” (right panel), hypo-phosphorylated YAP/TAZ translocate into the nucleus, where they bind to TEAD transcription factors to promote target gene transcription.
Non-coding RNAs comprise the vast majority of primary transcripts derived from genome encoding genes, similar to protein-coding RNAs. These ncRNAs are roughly classified into two major categories according to their length, namely, small ncRNAs (shorter than 200 nucleotides, including micro RNAs (miRNAs) and others) and long non-coding RNAs (lncRNAs, longer than 200 nucleotides).73,74) In addition, circular RNAs (circRNAs) have been identified as a novel class of non-coding RNA that has a covalently closed circular structure lacking both a 5′ cap and a 3′ tail. Convincing studies in recent years have revealed a regulatory network where ncRNAs interplay with the core components of the Hippo pathway to mediate physiological functions of the Hippo pathway. Among the multiple ncRNA subclasses, we summarize the emerging roles of miRNAs, lncRNAs and circRNAs in regulation of and by the Hippo pathway.3.1. Reciprocal Regulation between miRNA and the Hippo Pathway
MiRNAs are small RNAs of approximately 21–25 nucleotides in length; they do not encode functional proteins. MiRNA was first discovered in Caenorhabditis elegans as small RNA transcripts that suppress LIN-14 protein expression.75,76) MiRNAs negatively regulate protein expression at the post-transcriptional level by interacting with a complementary sequence typically located in the 3′ untranslated region (UTR) of the target transcript.77) Previous studies have revealed an important function of the Hippo pathway in the regulation of miRNA biogenesis (Fig. 3). YAP/TAZ in the nucleus have been found to bind to DEAD box helicase 17 (DDX17) (also known as p72) to suppress its association with the Microprocessor complex that regulates miRNA processing.78) Cell density-dependent activation of the Hippo pathway, thus, generally promotes global miRNA biogenesis.78) In cytoplasm, the hairpin structure of miRNA precursor is cleaved by the ribonuclease DICER to generate a mature miRNA duplex.79) Intriguingly, nuclear YAP/TAZ conversely stimulate the biogenesis of several miRNAs, such as miR-16, -21, -23a, and -107, by increasing DICER expression via the Let-7 family of miRNAs.80) In addition, YAP directly induces the transcription of certain miRNAs, such as miR-29.81) Another study demonstrated that NF2, an upstream activator of the Hippo pathway, promotes the biogenesis of the Let-7 family of miRNAs by sequestering its inhibitor, LIN28B.82) Therefore, the Hippo pathway may function as both a positive and negative regulator of miRNA biogenesis in a context- and target-dependent manner. Further investigations clarifying how the Hippo pathway takes advantage of this bidirectional regulation of miRNA biogenesis in both physiological and pathological contexts will broaden our understanding of miRNA biology regulated by the Hippo pathway.
In the nucleus, primary micro RNA (miRNA) transcript (pri-miRNA) is cleaved by the Microprocessor complex that contains DEAD box helicase 17 (DDX17) to generate pre-miRNA. The hairpin structure of the miRNA precursor is cleaved by the ribonuclease DICER in the cytoplasm, then loaded onto the miRNA-induced silencing complex (miRISC) to promote gene silencing of the target mRNA in the Hippo pathway. Nuclear YAP/TAZ bind to DDX17 and abrogate its association with the Microprocessor complex to inhibit global miRNA biogenesis. In contrast, YAP/TAZ also stimulate the biogenesis of several miRNAs by increasing the expression of DICER. Therefore, the Hippo pathway functions as both a positive and negative regulator of miRNA biogenesis in a context-dependent manner.
Following cleavage by DICER, a single strand miRNA is loaded onto Argonaute 2 (AGO2) protein as part of the miRNA-induced silencing complex (miRISC) to promote gene silencing of the target mRNA (Fig. 3). Those mature miRNAs in turn modulate the activity of the Hippo pathway. A large number of miRNAs have been linked to the Hippo pathway to date, the majority of which were characterized in the context of cancer biology.83) The molecular actions and biological effects of several miRNAs are highlighted in Table 1. Each miRNA displays distinct mRNA targeting in the Hippo pathway, and even the effect of the same miRNA on the Hippo pathway is cell-type- and context-dependent. For example, miR-200 family miRNAs (include five members; miR-200a, -200b, -200c, -141, and -429) are one of the well-known inhibitors of the epithelial mesenchymal transition that confers malignant properties to cancer cells.84) MiR-200a has been shown to directly suppress YAP in human breast cancer cells,85) as well as TAZ in colon cancer cells,86) yet the overexpression of the miR-200 family in the developing skin of mice has been reported to promote YAP nuclear localization by targeting multiple upstream components of the Hippo pathway.87) One possibility for the diverse functions of miRNAs in the regulation of the Hippo pathway is that miRNAs can target multiple components in the same pathway88); conversely, a single component in the Hippo pathway could be regulated by multiple miRNAs. This complexity adds an extra layer of divergent regulation of the Hippo pathway by miRNAs in different tissues and biological processes; an integrated view of the miRNA network that orchestrates the complex physiological and pathological functions of the Hippo pathway remains to be elucidated.
|miRNA||Target||Effect on the Hippo pathway||Biological function||Context||Reference|
|miR-9 and miR-137||CUL4A||Increases the expression of LATS1 by suppressing the expression of CUL4A that targets LATS1 for proteasomal degradation||Suppresses cancer cell proliferation and invasion||Gastric cancer||Deng et al., 2016109)|
|miR-29-3p||DNMT3B||Increases the expression of LATS1 by suppressing the expression of DNMT3B that promotes promoter methylation of LATS1 locus and consequent gene repression||Suppresses cancer cell proliferation and migration, as well as tumor growth in nude mice||Hepatocellular carcinoma||Wu et al., 2019110)|
|miR-199a-3p||TAOK1, β-TrCP, and NDR2||Increases protein expression and nuclear localization of YAP by suppressing multiple Hippo pathway components||Induces cardiomyocyte proliferation||Cardiomyocyte||Torrini et al., 2019111)|
|miR-200a||YAP||Decreases the expression of YAP by targeting 3′ UTR of those mRNA||Attenuates anoikis-induced apoptosis in cancer cells||Breast cancer||Yu et al., 201385)|
|miR-200 family (miR-200a, -200b, -200c, -141, and -429)||LATS1/2, and PTPN14||Promotes nuclear localization of YAP by suppressing multiple Hippo pathway components, but simultaneously represses YAP target genes, such as CTGF||Represses cell proliferation, migration, and formation of adherens junctions||Hair morphogenesis||Hoefert et al., 201887)|
|miR-302/367 cluster (miR-302a, -302b, -302c, -302d, and -367)||MOB1B, LATS2, and MST1||Promotes nuclear localization of YAP by suppressing multiple Hippo pathway components||Increases cardiomyocyte proliferation in embryonic and postnatal hearts, promotes adult cardiac regeneration after myocardial infarction||Heart development and regeneration||Tian et al., 2015112)|
|miR-302/367 cluster (miR-302a, -302b, -302c, -302d, and -367)||LATS2||Decreases the expression of LATS2 by targeting 3′ UTR of its mRNA||Promotes cancer cell proliferation, sphere formation, invasion, and tumor growth in nude mice||Prostate cancer||Guo et al., 2017113)|
|miR-375||YAP1, TEAD4 and CTGF||Decreases the expression of YAP, TEAD4, and CTGF by targeting 3′ UTR of those mRNA||Inhibits cancer cell proliferation and invasion, as well as tumor growth in nude mice||Gastric cancer||Kang et al., 2018114)|
|miR-506-3p||YAP||Suppresses the expression of YAP by targeting 3′ UTR of its mRNA||Not validated||Esophageal squamous cell carcinoma||Wang et al., 2019115)|
|miR-4269||TEAD1/4||Decreases the expression of TEAD1/4 by targeting 3′ UTR of those mRNA||Suppresses cancer cell proliferation and invasion, as well as tumor growth in nude mice||Gastric cancer||Zhou et al., 2017116)|
Recent advances in RNA-sequencing technology have revealed the existence of approximately 7500 small ncRNAs (including 1800 miRNAs) as well as 18000 lncRNAs, in addition to 20000 protein-coding genes in the human genome.89) As described above, the regulatory ncRNAs, such as miRNAs, play important roles in gene expression mainly by controlling the expression levels of the protein-coding RNAs. However, the physiological function of the vast majority of ncRNAs remains to be clarified. Although there has been scientific debate, one interesting hypothesis to explain the existence of a large number of ncRNAs in the human genome is the competing endogenous RNA (ceRNA) hypothesis.90) MiRNAs recognize their target mRNAs by using as few as 6–8 nucleotides at the 5′ end of the miRNA, namely the seed region.88) Recent studies have revealed that certain ncRNAs, including lncRNAs and, to a lesser extent, circRNAs, compete with mRNA for interaction with the seed region of miRNAs,90,91) and therefore, those ncRNAs can act as molecular sponges or decoys to suppress the targeting of mRNAs by miRNAs (Fig. 4). Indeed, experimentally designed decoy RNAs have been shown to act as molecular sponges to inhibit the function of miRNAs.92) In addition to the known functions of ncRNAs in transcriptional regulation, or in mediating protein–protein interaction,91,93) ncRNAs act as ceRNAs to regulate other RNA transcripts by competing for shared miRNAs.
MiRNAs function by mainly suppressing the expression levels of protein-coding mRNAs. Other types of non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), can regulate transcription, RNA splicing, and protein–protein interaction via direct binging. In the competing endogenous RNA (ceRNA) hypothesis, it is proposed that lncRNAs and circRNAs compete with mRNA for interaction with miRNAs, and therefore serve as molecular sponges to suppress the targeting of mRNAs by miRNAs. Thus, the ceRNA network involving lncRNA/circRNA–miRNA–mRNA regulates the activity of the Hippo pathway by multiple mechanisms.
We next discuss the emerging roles of lncRNAs and circRNAs in the regulation of the Hippo pathway.3.2. Regulation of the Hippo Pathway by lncRNA
LncRNAs are defined as RNA transcripts with lengths exceeding 200 nucleotides and not translated into proteins. LncRNAs are transcribed in both sense and antisense directions by RNA Polymerase II, then polyadenylated and spliced in the same fashion as mRNA93) (Fig. 5A). Mature lncRNA transcripts represent unique secondary structures that can interact with DNA, RNA, or proteins, and thereby modulate gene transcription, post-transcriptional gene expression, and also protein–protein interaction.93) Recent studies have revealed broad roles of lncRNAs in mediating numerous biological processes during disease development and progression,67,94) and lncRNAs are also emerging as an important mediator of the Hippo pathway. For instance, YAP in a complex with TEAD4 promotes the transcription of BCAR4 lncRNA, which subsequently modulates Hedgehog signaling to enhance the transcription of the key glycolytic enzymes.95) YAP activation thus promotes glycolysis in cancer cells via lncRNAs. As glucose metabolism is one of the potent regulators of the Hippo pathway,65) this study not only highlighted the signal crosstalk mediated by lncRNAs, but also revealed an intimate relationship between the Hippo pathway and glucose homeostasis. Notably, therapeutic delivery of locked nucleic acids targeting BCAR4 attenuated YAP-dependent glycolysis and breast cancer growth, suggesting a therapeutic potential for targeting the Hippo–lncRNA axis in cancer treatment.95) Similarly, YAP in complex with TCF4/β-catenin has been shown to promote the expression of MALAT1 lncRNA in liver cancer96) and colon cancer97) to enhance the tumorigenic properties of cancer cells, such as cell proliferation and migration. Of note, the tumor promoting effects of MALAT1 could be cell-type- and context-dependent, as it has been shown that MALAT1 suppresses breast cancer metastasis by inactivating TEAD-mediated transcription via direct binding.98) In addition, YAP has also been shown to function in suppressing certain lncRNA expression, such as MT1DP,99) though the precise underlying molecular mechanism awaits further elucidation. These studies highlight an important function of lncRNAs in mediating various functions downstream of the Hippo pathway.
(A) LncRNAs are transcribed in both sense and antisense directions, and mature lncRNA transcripts represent unique secondary structures that can interact with DNA, RNA, or proteins. LncRNAs thus modulate protein–protein interaction via direct binding in the regulation of the Hippo pathway. LncRNAs also function as ceRNAs to regulate the expression of Hippo pathway components, and conversely, YAP can affect the transcription of certain lncRNAs. (B) CircRNAs are single-stranded transcripts that have a covalent closed-loop structure resulting from a 3′ to 5′ end-joining event, namely back-splicing. CircRNAs function as ceRNAs, or they encode a small protein to modulate the activity of the Hippo pathway. YAP is reported to regulate the transcription of specific circRNAs.
LncRNAs also regulate the Hippo pathway through multiple mechanisms. As summarized in Table 2, many lncRNAs have been reported to affect the activity of the Hippo pathway, especially in the context of cancer cell growth and metastasis. Some lncRNA transcripts directly bind to the components of the Hippo pathway and modulate their protein–protein interaction. For example, the lncRNA MAYA provides a scaffold for the methyltransferase NSUN6 to promote MST1 methylation that leads to the inactivation of MST1 and consequent YAP/TAZ target gene activation in breast cancer cells.100) Another mechanism of action for lncRNA-mediated Hippo pathway regulation is that lncRNAs act as ceRNAs to suppress the targeting of mRNAs by miRNAs. This includes miR-200a-3p targeting by SNHG15 lncRNA.101) As described above, miR-200a targets YAP mRNA in human breast cancer cells.85) Similar effects have been observed in papillary thyroid carcinoma cells, where SNHG15 serves as a ceRNA to increase YAP expression by sponging miR-200a-3p.101) Therefore, the ceRNA network involving lncRNA–miRNA–mRNA regulates the complex activity of the Hippo pathway during cancer progression.
|lncRNA||Effect on the Hippo pathway||Biological function||Context||Reference|
|MALAT1||Prevents TEADs-YAP binding via direct binding, and inhibits their target gene expression||Suppresses cancer metastasis||Breast cancer||Kim et al., 201898)|
|MAYA||Induces inhibitory methylation of MST1 by serving as a scaffold for a methyltransferase complex||Promotes bone metastasis of cancer cells||Breast cancer||Li et al., 2017100)|
|Nkx2-2as||Increases the expression of LATS1/2 by functioning as a sponge for miR-103a, miR-107, and miR-548 m||Suppresses cancer cell proliferation and invasion, as well as tumor growth in nude mice||Medulloblastoma||Zhang et al., 2018117)|
|SNHG1||Increases the expression of YAP by functioning as a sponge for miR-375||Promotes cancer cell proliferation and migration||Laryngeal squamous cell carcinoma||Gao et al., 2018118)|
|SNHG15||Increases the expression of YAP by functioning as a sponge for miR-200a-3p||Promotes cell proliferation and inhibits apoptosis, supporting tumor growth in nude mice||Papillary thyroid cancer||Wu et al., 2018101)|
|ZFAS1||Increases the expression of YAP and TEAD1 by functioning as a sponge for miR-27a, miR-15a, and miR-16||Promotes cancer cell proliferation and invasion, as well as tumor growth in nude mice||Prostate cancer||Cui et al., 2019119)|
CircRNAs are single-stranded transcripts that have a covalent closed-loop structure resulting from a 3′ to 5′ end-joining event, which protects them from degradation by ribonuclease and thus makes them more stable compared to linear RNAs.91,102) CircRNAs are presumably generated by a low-efficient splicing process, namely, back-splicing circularization, and their biogenesis is closely associated with the production of a linear RNA counterpart during splicing. Apart from canonical splicing that joins the upstream 5′ end of the intron (donor site) with the downstream 3′ end of the intron (acceptor site), back-splicing ligates a downstream 5′ donor site reversely with an upstream 3′ acceptor site, resulting in a covalently closed transcript (circRNA), together with an alternatively spliced linear RNA with skipped exons.91,102) (Fig. 5B) Although the functions of most circRNAs are still uncharacterized, recent studies have linked some circRNAs to the Hippo pathway, where circRNAs serve as ceRNAs to mediate miRNA functions. The transcription complex involving YAP, TEAD1, and mutant p53 has been shown to enhance the expression of the tumor-promoting circRNA circPVT1, which suppresses miR-497-5p expression to promote cell proliferation.103) Intriguingly, circPVT1 forms a feed-forward loop to enhance its own expression by directly binding to YAP, suggesting an important function of circRNA downstream of the Hippo pathway in the progression of squamous cell carcinoma.103) CircRNAs also regulate the activity of the Hippo pathway, as evidenced by a study demonstrating that circ_104075 promotes YAP expression by sequestering its suppressor miRNA miR-582-3p in hepatocellular carcinoma.104) Similarly, circLARP4 inhibits cell proliferation and invasion in gastric cancer by functioning as a sponge for miR-424-5p that suppresses LATS1 expression.105) Notably, another study has demonstrated an interesting mechanism: the circRNA circPPP1R12A actually encodes a small protein to enhance YAP-dependent tumorigenesis by inhibiting the Hippo pathway through a currently uncharacterized mechanism involving downregulation of MST1 and LATS1.106) Although our understanding of the interplay between the Hippo pathway and circRNA biology is just emerging, these findings highlight a divergent regulation of the Hippo pathway by a regulatory network involving various types of ncRNAs.
Over the past decade, our understanding of the Hippo signaling network has been expanded considerably with the identification of upstream regulatory signals as well as downstream biological functions. Despite continuous efforts to develop drugs that target the Hippo pathway for the treatment of human diseases, specific potent inhibitors have not yet been established. Previous strategies for such drug development have been associated with targeting the interaction between YAP/TAZ and TEAD transcription factors,13) which are fundamentally difficult to target. It is generally easier to design an oligonucleotide that binds RNA and inhibits its function than to find a small molecule that directly inhibits the protein’s function.107) Indeed, certain locked nucleic acids that target ncRNAs have been shown to affect the activity of the Hippo pathway, modulating several biological processes.95,100,108) Thus, the emerging link between the Hippo pathway and ncRNAs not only contributes to our understanding of the composition of the divergent Hippo network, but also, when further dissected, provides a new therapeutic approach to target this pathway in the treatment of human diseases, such as cancer and tissue degeneration. Further investigations to clarify this link will have important implications for future drug discovery.
The authors thank Dr. Kazuhiko Maeda (Osaka University) and all members of the Moroishi laboratory for critical discussion and constructive comments. Work in the Moroishi laboratory is supported by JST PRESTO [JPMJPR17HA], JSPS KAKENHI [JP18K19433 and JP18H02438], Mitsubishi Foundation, Naito Foundation, Nakajima Foundation, Daiichi Sankyo Foundation of Life Science, Mochida Memorial Foundation for Medical and Pharmaceutical Research, MSD Life Science Foundation Public Interest Incorporated Foundation, Astellas Foundation for Research on Metabolic Disorders, Bristol-Myers Squibb Foundation, Yasuda Medical Foundation, Shinnihon Foundation of Advanced Medical Treatment Research, Uehara Memorial Foundation, Kao Foundation for Arts and Sciences, Taiju Life Social Welfare Foundation, and Japan Foundation for Applied Enzymology.
The authors declare no conflict of interest.